Medulloblastomas: a correlative study of MIB-1 proliferation index along with expression of c-Myc, ERBB2, and anti-apoptotic proteins along with histological typing and clinical outcome

Abstract Context.—Angiogenesis and the cell proliferation index can predict the prognosis of invasive breast carcinoma; however, little is known of their roles in noninvasive tumor. Objective.—To investigate the correlation of microvessel density and cell proliferation index with other histologic parameters (histologic type, nuclear grade, and mitotic count) in 65 cases of noninvasive carcinoma of the breast. Design.—Formalin-fixed, paraffin-embedded tissues from 65 cases of carcinoma in situ of the breast were immunostained with antibody against factor VIII antigen and proliferation-associated nuclear antigen MIB-1. The microvessel density was measured by counting the total number of microvessels around the carcinoma in situ per 10 low-power microscopic fields. The cell proliferation index was calculated by counting MIB-1–positive nuclei in 100 tumor cells. A χ2 test and Spearman rank correlation test were used for statistical analysis. Results.—The microvessel density and cell proliferation index of comedo-type, high-nuclear-grade ductal carcinomas in situ are significantly higher than those of either noncomedo type ductal carcinomas in situ or lobular carcinoma in situ (P < .001). Conclusions.—Angiogenesis and the cell proliferation index are active biological processes and may be considered as markers to separate low- and high-risk patients with noninvasive breast carcinomas.

Download Full-text

Clinical outcome and molecular characterization of pediatric glioblastoma treated with postoperative radiotherapy with concurrent and adjuvant temozolomide: a single institutional study of 66 children

Neuro-Oncology Practice ◽

10.1093/nop/npv024 ◽

2015 ◽

Vol 3 (1) ◽

pp. 39-47 ◽

Cited By ~ 4

Author(s):

Rakesh Jalali ◽

Anupam Rishi ◽

Jayant S. Goda ◽

Epari Sridhar ◽

Mamta Gurav ◽

...

Keyword(s):

Overall Survival ◽

Clinical Outcome ◽

Labeling Index ◽

Molecular Profile ◽

Mgmt Methylation ◽

P53 Overexpression ◽

P53 Expression ◽

Egfr Amplification ◽

Adjuvant Temozolomide ◽

Mib 1

Abstract Background Glioblastoma (GBM) in children is rare. Pediatric GBM have a distinct molecular profile as compared to adult GBM. There are relatively few studies of pediatric GBMs and no standard of care on adjuvant therapy. We aimed to evaluate the clinical outcome and molecular profile of pediatric GBM. Methods and Materials Between 2004 and 2013, 66 consecutive children with histologically proven GBM were identified from our database. The majority of the children underwent maximal safe resection followed by focal radiotherapy with concurrent and adjuvant temozolomide. Immunohistochemical staining was performed for p53, MIB-1 labeling index, MGMT overexpression, and EGFR amplification and isocitrate dehydrogenase (IDH1) R132H point mutation. Survival and impact of possible prognostic factors on outcomes were analyzed. Result Median survival was 15 months. The overall survival rate at 1 year was 62%, at 2 years was 30%, and at 3 years was 27%. Patients with thalamic tumors (P < .001), incompletely resected tumors (P < .00001), and tumors with MIB-1 labeling index >25% (P < .002) had poor overall survival rates. p53 was overexpressed in 74% of patients, MGMT promoter methylation was seen in 37% of patients, IDH1 mutation was seen in 4% of patients, and no patients had EGFR amplification. MGMT methylation and p53 overexpression did not impact survival. Conclusions Clinical outcome of pediatric GBM is similar to that reported for adult GBM. The frequency of p53 overexpression is higher than in adult GBM, while MGMT methylation, IDH1 mutations and EGFR amplification is lower than in adult GBM. MGMT methylation and p53 expression status do not have any prognostic significance.

Download Full-text

Relation between HPV-DNA and expression of p53, bcl-2, p21WAF-1, MIB-1, HER-2/neu and DNA ploidy in early cervical carcinoma: Correlation with clinical outcome

Oncology Reports ◽

10.3892/or.12.1.169 ◽

2004 ◽

Author(s):

M. Graflund ◽

B. Sorbe ◽

S. Sigurdardóttir ◽

M. Karlsson

Keyword(s):

Clinical Outcome ◽

Cervical Carcinoma ◽

Dna Ploidy ◽

Hpv Dna ◽

Her 2 ◽

Mib 1

Download Full-text

Prognostic value of MIB-1 proliferation index in solitary fibrous tumors of the pleura implemented in a new score – a multicenter study

Respiratory Research ◽

10.1186/s12931-017-0693-8 ◽

2017 ◽

Vol 18 (1) ◽

Cited By ~ 11

Author(s):

Matthias Diebold ◽

Alex Soltermann ◽

Selma Hottinger ◽

Sarah R. Haile ◽

Lukas Bubendorf ◽

...

Keyword(s):

Multicenter Study ◽

Prognostic Value ◽

Proliferation Index ◽

Solitary Fibrous Tumors ◽

Mib 1

Download Full-text

Medulloblastoma: evaluation of proliferative index by monoclonal antibody Mib-1, its prognostic correlation and therapeutic implications

Arquivos de Neuro-Psiquiatria ◽

10.1590/s0004-282x2003000400004 ◽

2003 ◽

Vol 61 (3A) ◽

pp. 547-551 ◽

Cited By ~ 4

Author(s):

Antonio Fernandes Ferrari ◽

Maria Betânia Mahler Araújo ◽

Paulo Henrique Aguiar ◽

José Pindaro Pereira Plese

Keyword(s):

Monoclonal Antibody ◽

Prognostic Value ◽

Cellular Proliferation ◽

Proliferation Index ◽

Histopathological Diagnosis ◽

Central Nervous System Tumor ◽

Proliferative Index ◽

The Mean ◽

Monoclonal Antibody Mib 1 ◽

Mib 1

In the past few years, the monoclonal antibody MIB-1 has been used by researchers in order to retrospectively study paraffin imbibed tumor fragments. The medulloblastoma is the most common malignant central nervous system tumor in childhood. The objectives were: determination of the mean Mib-1 LI value from these patients, as well as the prognostic value of the method.This retrospective study represents an analysis of the cellular proliferation index of posterior fossa medulloblastomas collected from 22 patients at A.C. Camargo Hospital, from January 1990 to December 1999. The histopathological diagnosis was confirmed by H&E and proliferative index (LI) was achived with Mib-1 which detects proliferating cells during G1, G2, S and M phases.The results demostrated that the mean Mib-1 was 30,1%, and ranged from 5,2% to 62,0%.In conclusion, this method has prognostic value, has to be used as routine for patients harboring medulloblastomas and the ones who have PI greater than the mean value found in this study, should be treated aggressively.

Download Full-text

Biological mechanisms that trigger breast cancer (BC) tumor progression are molecular subtype dependent

Journal of Clinical Oncology ◽

10.1200/jco.2007.25.18_suppl.10581 ◽

2007 ◽

Vol 25 (18_suppl) ◽

pp. 10581-10581 ◽

Cited By ~ 1

Author(s):

C. Sotiriou ◽

C. Desmedt ◽

B. Haibe-Kains ◽

A. Harris ◽

D. Larsimont ◽

...

Keyword(s):

Breast Cancer ◽

Immune Response ◽

Clinical Outcome ◽

Tumor Size ◽

Tumor Invasion ◽

Molecular Mechanisms ◽

Molecular Subtypes ◽

Proliferation Index ◽

P Value ◽

Prognostic Impact

10581 Background: We have recently developed several gene expression indices related to hallmarks of breast cancer involving various biological processes such as tumor invasion, impairment of immune response, sustained angiogenesis, evasion of apoptosis and self- sufficiency in growth signal, and investigated their impact on clinical outcome. Here, we aim to refine our biological understanding and the prognostic impact of these indices according to the previously described molecular subtypes based on the estrogen (ER) and ERBB2 receptors. Methods: Each of these indices were developed in a series of 581 BC samples and then computed on several publicly available microarray studies totaling over 2100 BC patients. Multivariate analyses were used to study the dependency patterns between these indices, the molecular subtypes and their impact on survival. Results: ER-/ERBB2- and ERBB2+ subgroups were significantly associated with high expression levels of the proliferation, tumor invasion, angiogenesis and immune response indices. Multivariate analysis showed that in the ER+/ERBB2- subgroup, only tumor size and the proliferation and tumor invasion indices were significantly associated with clinical outcome, with the proliferation index having the largest HR and most significant p-value (HR 3.25; CI 2.31–4.56; p=1.2 10-11). In contrast, in the ER-/ERBB2- subgroup, only tumor size (HR 2.08; CI 1.14–3.81; p=0.01) and immune response index (HR 0.66; CI 0.46–0.95; p=0.02) were associated with prognosis whereas in the ERBB2+ tumors only nodal status (HR 3.40; CI 0.96–12.10; p=0.05) and tumor invasion index (HR 3.03; CI 1.32–6.95; p=0.009) showed significant association with survival. Of interest, proliferation index lost its significance as almost all ER- /ERBB2- and ERBB2 + tumors showed high proliferation levels. Conclusions: Although proliferation seems to be the strongest parameter predicting clinical outcome in ER+/ERBB2- subtype, immune response and tumor invasion appear to be the main molecular mechanisms associated with prognosis in the ER-/ERBB2- and ERBB2+ subgroups respectively. Defining these clinico-genomic models in the specific molecular subgroups will be the key to success for personalized medicine. No significant financial relationships to disclose.

Download Full-text

MIB-1 proliferation index correlates with survival in pleural malignant mesothelioma

Histopathology ◽

10.1046/j.1365-2559.2000.00793.x ◽

2000 ◽

Vol 36 (1) ◽

pp. 26-31 ◽

Cited By ~ 25

Author(s):

Comin ◽

Anichini ◽

Boddi ◽

Novelli ◽

Dini

Keyword(s):

Malignant Mesothelioma ◽

Proliferation Index ◽

Pleural Malignant Mesothelioma ◽

Mib 1

Download Full-text

Assessment of Proliferation Index with MIB-1 as a Prognostic Factor in Radiation Therapy for Cervical Cancer

Gynecologic Oncology ◽

10.1006/gyno.2000.5950 ◽

2000 ◽

Vol 79 (2) ◽

pp. 300-304 ◽

Cited By ~ 7

Author(s):

Mitsuaki Suzuki ◽

Shizuka Tsukagoshi ◽

Yasushi Saga ◽

Michitaka Ohwada ◽

Ikuo Sato

Keyword(s):

Cervical Cancer ◽

Radiation Therapy ◽

Prognostic Factor ◽

Proliferation Index ◽

Mib 1

Download Full-text

Qualitative analysis of spinal intramedullary lesions using PET/CT

Journal of Neurosurgery Spine ◽

10.3171/2015.2.spine141254 ◽

2015 ◽

Vol 23 (5) ◽

pp. 613-619 ◽

Cited By ~ 12

Author(s):

Kentaro Naito ◽

Toru Yamagata ◽

Hironori Arima ◽

Junya Abe ◽

Naohiro Tsuyuguchi ◽

...

Keyword(s):

Fdg Pet ◽

Proliferation Index ◽

Low Grade ◽

Tumor Proliferation ◽

High Grade ◽

Pet Ct ◽

Grade Malignancy ◽

High Grade Malignancy ◽

Met Pet ◽

Mib 1

OBJECT Although the usefulness of PET for brain lesions has been established, few reports have examined the use of PET for spinal intramedullary lesions. This study investigated the diagnostic utility of PET/CT for spinal intramedullary lesions. METHODS l-[methyl-11C]-methionine (MET)- or [18F]-fluorodeoxyglucose (FDG)-PET/CT was performed in 26 patients with spinal intramedullary lesions. The region of interest (ROI) within the spinal cord parenchyma was placed manually in the axial plane. Maximum pixel counts in the ROIs were normalized to the maximum standardized uptake value (SUVmax) using subject body weight. For FDG-PET the SUVmax was corrected for lean body mass (SULmax) to exclude any influence of the patient’s body shape. Each SUV was analyzed based on histopathological results after surgery. The diagnostic validity of the SUV was further compared with the tumor proliferation index using the MIB-1 monoclonal antibody (MIB-1 index). RESULTS A total of 16 patients underwent both FDG-PET and MET-PET, and the remaining 10 patients underwent either FDG-PET or MET-PET. Pathological diagnoses included high-grade malignancy such as glioblastoma multiforme, anaplastic astrocytoma, or anaplastic ependymoma in 5 patients; low-grade malignancy such as hemangioblastoma, diffuse astrocytoma, or ependymoma in 12 patients; and nonneoplastic lesion including cavernous malformation in 9 patients. Both FDG and MET accumulated significantly in high-grade malignancy, and the SULmax and SUVmax correlated with the tumor proliferation index. Therapeutic response after chemotherapy or radiation in high-grade malignancy was well monitored. However, a significant difference in SULmax and SUVmax for FDG-PET and MET-PET was not evident between low-grade malignancy and nonneoplastic lesions. CONCLUSIONS Spinal PET/CT using FDG or MET for spinal intramedullary lesions appears useful and practical, particularly for tumors with high-grade malignancy. Differentiation of tumors with low-grade malignancy from nonneoplastic lesions may still prove difficult. Further technological refinement, including the selection of radiotracer or analysis evaluation methods, is needed.

Download Full-text